Neuronetics, Inc.

NASDAQ:STIM

Medical - Diagnostics & Research

Healthcare
$1.25 +0.31%

+$0.00 today

Market cap
$97.16M
Beta
1.04
P/E (TTM)
-2.3
EPS (TTM)
-$0.53
52W Low $0.80High $4.85

Volume 2.55M

Average 2.44M

STIM Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Neuronetics, Inc.NASDAQ: STIM

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $23.79M fell 5.4% year over year, behind the +14.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.

Context

  • Selling, general & admin amounted to 65.1% of revenue in FY2025, down 36.3 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of $161.83M (+66.6%) for the fiscal year ending Dec 2026, a step up from the +27.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$23.79M-5.2% QoQ
Last fiscal yearDec 2025
$97.16M+27.9% YoY
LTMMar 2026
$95.81M+14.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.4%+66.8%+72.2 pp
1 year+27.9%+66.6%+38.6 pp
3-year CAGR+8.8%+25.7%+16.9 pp
5-year CAGR+18.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
97.16M USD
Year-over-year change
+27.9%
4-year CAGR
+11.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How STIM compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.8% is the 4th highest of 10, against a peer median of -2.4%.
  • Selling, general & admin amounts to 63.2% of revenue for STIM, versus a peer median of 91.6%.
STIM Competitors
Selling, General & Admin for STIM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STIMNeuronetics, Inc.LTM Mar 2026$95.81M USD+14.8%+8.8%63.2%
PREPrenetics Global LimitedLTM Mar 2026$95.47M USD+58.4%+7.6%83.9%
ATLNAtlantic International Corp.LTM Dec 2025$91.29M USD+42.6%+29.3%20.9%
OSUROraSure Technologies, Inc.LTM Mar 2026$74.99M USD-2.4%-14.3%66.4%
NYXHNyxoah S.A.LTM Mar 2026€51.66M EUR+54.2%+35.0%316.6%
CDXSCodexis, Inc.LTM Mar 2026$43.75M USD-19.9%-3.4%56.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$31.65M USD-26.4%-17.7%91.6%
PROFProfound Medical Corp.LTM Mar 2026$30.61M USD-29.9%+22.1%162.2%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$29.38M USD+2.8%+28.6%4753.4%
OABIOmniAb, Inc.LTM Mar 2026$26.47M USD-12.7%+5.5%91.6%
Peer median (excluding STIM) —-2.4%+7.6%91.6%

Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M65.21M71.35M74.89M149.16M
Cost of Revenue11.65M15.48M19.64M20.73M76.85M
Gross Profit43.66M49.72M51.71M54.16M72.31M
Gross Margin78.9%76.3%72.5%72.3%48.5%
Research & Development7.92M9.34M9.52M12.77M6.58M
Selling, General & Admin63.3M75.5M72.74M75.95M97.16M
Operating Expenses71.22M84.83M82.26M88.72M103.74M
Depreciation & Amortization1.06M1.65M2.01M2.07M3.47M
EBITDA(26.81M)(31.96M)(22.76M)(34.37M)(27.12M)
EBITDA Margin-48.5%-49.0%-31.9%-45.9%-18.2%
Operating Income(27.56M)(35.11M)(30.55M)(34.56M)(31.44M)
Operating Margin-49.8%-53.8%-42.8%-46.2%-21.1%
Interest Income0024K00
Interest Expense3.3M3.6M5.42M7.29M8.42M
Other Income / Expenses(3.61M)(2.1M)365K(9.18M)(7.56M)
Income Before Tax(31.17M)(37.21M)(30.19M)(43.74M)(39M)
Pre-Tax Margin-56.4%-57.1%-42.3%-58.4%-26.1%
Income Tax Expense00(24K)(14K)0
Net Income(31.19M)(37.16M)(30.19M)(43.71M)(39M)
Net Margin-56.4%-57.0%-42.3%-58.4%-26.1%
EPS (Basic)(1.22)(1.38)(1.05)(1.38)(0.59)
EPS (Diluted)(1.22)(1.38)(1.05)(1.38)(0.59)
Weighted Avg Shares25.48M26.9M28.66M31.73M65.95M
Weighted Avg Shares (Diluted)25.48M26.9M28.66M31.73M65.95M

Neuronetics, Inc.

NASDAQ:STIM

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.